Recombinant E. coli dualistic role as an antigen-adjuvant delivery vehicle for oral immunization

Maria Gomes-Solecki, Luciana Richer

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Escherichia coli is the mainstay tool for fundamental microbiology research due to its ease of cultivation and safety. Auxotrophic strains of the K-12 and B lineages of E. coli are the organisms of choice to produce recombinant proteins. Components present in the cell envelope of bacteria are also potent immune modulators and have been used to develop adjuvants. We used live E. coli, after induction of recombinant protein expression, to develop a vehicle which has a dualistic function of producing vaccine while presenting itself as the adjuvant to deliver oral vaccines against a number of infectious diseases, including Lyme disease. Here, we give an example using E. coli expressing B. burgdorferi Outer Surface Protein A, which was proven effective in reducing B. burgdorferi burden in infected ticks after a 5-year field trial of a baited formulation containing this reservoir targeted vaccine.

Original languageEnglish (US)
Title of host publicationMethods in Molecular Biology
PublisherHumana Press Inc.
Pages347-357
Number of pages11
DOIs
StatePublished - Jan 1 2018

Publication series

NameMethods in Molecular Biology
Volume1690
ISSN (Print)1064-3745

Fingerprint

Immunization
Escherichia coli
Antigens
Vaccines
Recombinant Proteins
Lyme Disease
Ticks
Microbiology
Communicable Diseases
Bacteria
Safety
Research

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Genetics

Cite this

Gomes-Solecki, M., & Richer, L. (2018). Recombinant E. coli dualistic role as an antigen-adjuvant delivery vehicle for oral immunization. In Methods in Molecular Biology (pp. 347-357). (Methods in Molecular Biology; Vol. 1690). Humana Press Inc.. https://doi.org/10.1007/978-1-4939-7383-5_27

Recombinant E. coli dualistic role as an antigen-adjuvant delivery vehicle for oral immunization. / Gomes-Solecki, Maria; Richer, Luciana.

Methods in Molecular Biology. Humana Press Inc., 2018. p. 347-357 (Methods in Molecular Biology; Vol. 1690).

Research output: Chapter in Book/Report/Conference proceedingChapter

Gomes-Solecki, M & Richer, L 2018, Recombinant E. coli dualistic role as an antigen-adjuvant delivery vehicle for oral immunization. in Methods in Molecular Biology. Methods in Molecular Biology, vol. 1690, Humana Press Inc., pp. 347-357. https://doi.org/10.1007/978-1-4939-7383-5_27
Gomes-Solecki M, Richer L. Recombinant E. coli dualistic role as an antigen-adjuvant delivery vehicle for oral immunization. In Methods in Molecular Biology. Humana Press Inc. 2018. p. 347-357. (Methods in Molecular Biology). https://doi.org/10.1007/978-1-4939-7383-5_27
Gomes-Solecki, Maria ; Richer, Luciana. / Recombinant E. coli dualistic role as an antigen-adjuvant delivery vehicle for oral immunization. Methods in Molecular Biology. Humana Press Inc., 2018. pp. 347-357 (Methods in Molecular Biology).
@inbook{7010ef6225134ae68fd777474513fd6b,
title = "Recombinant E. coli dualistic role as an antigen-adjuvant delivery vehicle for oral immunization",
abstract = "Escherichia coli is the mainstay tool for fundamental microbiology research due to its ease of cultivation and safety. Auxotrophic strains of the K-12 and B lineages of E. coli are the organisms of choice to produce recombinant proteins. Components present in the cell envelope of bacteria are also potent immune modulators and have been used to develop adjuvants. We used live E. coli, after induction of recombinant protein expression, to develop a vehicle which has a dualistic function of producing vaccine while presenting itself as the adjuvant to deliver oral vaccines against a number of infectious diseases, including Lyme disease. Here, we give an example using E. coli expressing B. burgdorferi Outer Surface Protein A, which was proven effective in reducing B. burgdorferi burden in infected ticks after a 5-year field trial of a baited formulation containing this reservoir targeted vaccine.",
author = "Maria Gomes-Solecki and Luciana Richer",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/978-1-4939-7383-5_27",
language = "English (US)",
series = "Methods in Molecular Biology",
publisher = "Humana Press Inc.",
pages = "347--357",
booktitle = "Methods in Molecular Biology",

}

TY - CHAP

T1 - Recombinant E. coli dualistic role as an antigen-adjuvant delivery vehicle for oral immunization

AU - Gomes-Solecki, Maria

AU - Richer, Luciana

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Escherichia coli is the mainstay tool for fundamental microbiology research due to its ease of cultivation and safety. Auxotrophic strains of the K-12 and B lineages of E. coli are the organisms of choice to produce recombinant proteins. Components present in the cell envelope of bacteria are also potent immune modulators and have been used to develop adjuvants. We used live E. coli, after induction of recombinant protein expression, to develop a vehicle which has a dualistic function of producing vaccine while presenting itself as the adjuvant to deliver oral vaccines against a number of infectious diseases, including Lyme disease. Here, we give an example using E. coli expressing B. burgdorferi Outer Surface Protein A, which was proven effective in reducing B. burgdorferi burden in infected ticks after a 5-year field trial of a baited formulation containing this reservoir targeted vaccine.

AB - Escherichia coli is the mainstay tool for fundamental microbiology research due to its ease of cultivation and safety. Auxotrophic strains of the K-12 and B lineages of E. coli are the organisms of choice to produce recombinant proteins. Components present in the cell envelope of bacteria are also potent immune modulators and have been used to develop adjuvants. We used live E. coli, after induction of recombinant protein expression, to develop a vehicle which has a dualistic function of producing vaccine while presenting itself as the adjuvant to deliver oral vaccines against a number of infectious diseases, including Lyme disease. Here, we give an example using E. coli expressing B. burgdorferi Outer Surface Protein A, which was proven effective in reducing B. burgdorferi burden in infected ticks after a 5-year field trial of a baited formulation containing this reservoir targeted vaccine.

UR - http://www.scopus.com/inward/record.url?scp=85032009690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032009690&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-7383-5_27

DO - 10.1007/978-1-4939-7383-5_27

M3 - Chapter

C2 - 29032558

AN - SCOPUS:85032009690

T3 - Methods in Molecular Biology

SP - 347

EP - 357

BT - Methods in Molecular Biology

PB - Humana Press Inc.

ER -